InjectionMRP Under Process
Official PMBI MRP is being updated for catalog code 2823.
Locate Jan Aushadhi KendraClinical Overview
Testosterone Enanthate Injection 250 mg/ml is a long-acting esterified androgen in a sterile sesame/castor oil depot vehicle on the WHO Model List of Essential Medicines. Cleaved slowly by serum esterases, it releases bioidentical testosterone which binds to androgen receptors, restoring normal male physiological testosterone levels, promoting secondary sexual characteristics, nitrogen retention, bone mineralization, erythropoiesis, and libido. Indicated for male hypogonadism (primary testicular failure or hypogonadotropic hypogonadism), delayed puberty in adolescent males, and female-to-male (transmasculine) gender-affirming hormone therapy.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
For Deep Intramuscular (IM) injection ONLY: 250 mg deep IM into the gluteal muscle every 2 to 4 weeks for replacement therapy, administered strictly by a healthcare professional. Never administer intravenously. Periodic monitoring of serum total testosterone, hematocrit/hemoglobin, lipid profile, and prostate-specific antigen (PSA) is mandatory.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Polycythemia (elevated hematocrit), injection site soreness, acne, gynecomastia, fluid retention/edema, increased libido, and aggressive mood changes. Rare/Severe: Venous thromboembolism (DVT/PE), worsening sleep apnea, hepatotoxicity, prostatic hypertrophy/progression of latent prostate cancer, and cardiovascular events.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Secondary exposure risk in women and children; polycythemia and cardiovascular risks. Strictly contraindicated in suspected or confirmed carcinoma of the prostate or male breast, pregnancy (teratogenic), severe congestive heart failure, and severe hepatic/renal disease. Hematocrit >54% requires dose withholding or therapeutic phlebotomy.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Gynecological, Obstetric & Endocrinological Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice or reproductive healthcare guidance. Hormonal medications, uterotonics, corticosteroids, fertility therapies, and emergency contraceptives have profound systemic actions and must be administered strictly under the supervision of a registered gynecologist, obstetrician, or endocrinologist.